The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a greater substantial reduction in body size and enhance metabolic func